Insider Shareholders with Direct Ownership of Revance Therapeutics, Inc. (RVNC)
This section provides a comprehensive overview of the insiders with direct ownership of Revance Therapeutics, Inc. (RVNC). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Revance Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Dustin S Sjuts
President |
229,660 | 96,174 | 167,550 $430,603 | 30 |
Mar 18, 2024
Reduced 5.21%
|
|
Abhay Joshi
COO, President of R&D |
40,120 | 21,244 | 120,708 $310,219 | 7 |
Mar 15, 2022
Reduced 2.11%
|
|
Aubrey Rankin
Director |
41,905 | 15,685 | 94,091 $241,813 | 5 |
Mar 15, 2022
Reduced 1.44%
|
|
Philip J. Vickers
Director |
10,072 | 0 | 29,722 $76,385 | 2 |
May 04, 2022
Added 16.93%
|
|
Mark J Foley
President & CEO |
1,298,715 | 1,712,215 | 0 $0 | 32 |
Feb 06, 2025
Reduced 100.0%
|
|
Tobin Schilke
CFO |
293,729 | 333,287 | 0 $0 | 43 |
Feb 06, 2025
Reduced 100.0%
|
| 35,006 | 51,506 | 0 $0 | 7 |
Feb 06, 2025
Reduced 100.0%
|
|
| 28,606 | 43,606 | 0 $0 | 6 |
Feb 06, 2025
Reduced 100.0%
|
|
|
Dwight Moxie
CLO & GC |
264,887 | 289,887 | 0 $0 | 24 |
Feb 06, 2025
Reduced 100.0%
|
| 20,784 | 20,784 | 0 $0 | 5 |
Feb 06, 2025
Reduced 100.0%
|
|
| 28,606 | 45,106 | 0 $0 | 6 |
Feb 06, 2025
Reduced 100.0%
|
|
| 28,606 | 43,606 | 0 $0 | 6 |
Feb 06, 2025
Reduced 100.0%
|
|
| 34,061 | 34,061 | 0 $0 | 9 |
Feb 06, 2025
Reduced 100.0%
|
|
| 31,675 | 31,675 | 0 $0 | 7 |
Feb 06, 2025
Reduced 100.0%
|
|
|
David Hollander
CMO & Global Therapeutics Lead |
0 | 108,853 | 0 $0 | 3 |
Feb 06, 2025
Reduced 100.0%
|
|
Erica Jordan
Chief Commercial Officer |
0 | 117,256 | 0 $0 | 3 |
Feb 06, 2025
Reduced 100.0%
|